News

Michael Herce, MD, MPH, MSCR, discusses this concept and how it works to improve access to healthcare for populations who have been disproportionately burdened by various infectious diseases such as HIV, tuberculosis, and COVID-19.

Bluejay Therapeutics’ investigational therapy, brelovitug, offers weekly self-administered injections and will be studied against the only approved treatment outside the US.

41 cases of nongroupable N meningitidis conjunctivitis were identified at Joint Base San Antonio-Lackland, highlighting diagnostic, treatment, and surveillance implications for congregate living settings.

From COVID-19 antivirals to RSV, influenza, malaria, and gram-negative infections, new research highlights both advances and ongoing challenges in infectious disease prevention and treatment.

Up to 2 million people in low- and lower-middle-income countries may gain access to the long-acting PrEP option under a three-year, no-profit agreement.

In the second interview segment with leaders from UNC's Special Pathogen Center, they discuss what it is like to be in the field during an outbreak caring for patients with high-consequence infectious diseases, and offer insights on how well prepared the US is for these situations.

In the midst of many changes surrounding aminoglycosides over the past several years, clinicians may be left wondering if these agents still have a role in modern clinical practice. This article summarizes changes impacting aminoglycosides, discusses where these agents may still have a role in the context of gram-negative infections, and explores future areas of study.

David Margolis, MD discusses his team’s work at UNC looking at combination treatment that includes the cancer drug, vorinostat, and immunotherapy as a potential HIV cure.

The financing supports phase 3 evaluation of Sidiprev, a first-in-class, nonantibiotic therapy designed to prevent C difficile infections, a leading US health care–associated threat.

WHO and HRP highlight new research on HIV communication, STI priorities, and inclusive strategies to strengthen sexual health worldwide.

This becomes the first state in the United States to do so, and of course, this decision will affect the childhood vaccine schedule in Florida. Infectious Diseases Society of America (IDSA) President, Tina Tan, MD, weighs in on this decision and what this could mean for an increase of vaccine-preventable diseases and who would be vulnerable to them.

Single-center randomized trial shows lower infection rates and extended time to SARS-CoV-2 infection, though larger studies are needed to confirm findings.

Iterum Therapeutics has launched its sulopenem etzadroxil and probenecid (Orlynvah), which is the first and only oral penem antibiotic in the US.

CDC survey found increased vaccination coverage among adolescents in 2024, with the exception of HPV, as childhood vaccinations decline.

Jonathan Parr, MD, MPH, discusses his research about this deadly and burdensome disease and how he and his team identify these parasitic strains with a combination of epidemiologic field work and the latest laboratory technology.

Supported by phase 3 SCORPIO-PEP trial data, ensitrelvir could become the first oral therapy to prevent COVID-19 following exposure, with an FDA decision due June 16, 2026.

In the DAN-RSV trial of 131,000 participants, RSVpreF lowered overall cardiorespiratory hospitalizations but showed no significant reduction in cardiovascular events.

Ciprofloxacin monotherapy was non-inferior to aminoglycoside/ciprofloxacin combination for bubonic plague in multi-year trial in endemic region.

Pranita Tamma, MD, MHS, continues her conversation about a study she was involved in that compared ceftolozane-tazobactam and ceftazidime-avibactam. She discusses how clinicians can help reduce the emergence of antimicrobial resistance by using higher doses with extended infusions, limiting treatment duration, ensuring source control, and avoiding unnecessary dose reductions during CRRT.

Results from a Danish trial of more than 330,000 adults 65 years or older found high- and standard-dose influenza vaccines had similar effectiveness against influenza or pneumonia-related hospitalizations.

Robert Hopkins, Jr, MD, medical director of the National Foundation for Infectious Diseases (NFID), discusses what patients are asking about with regards to the vaccines and what the general public should continue to know about their medical value.

This week, expert insights highlighted progress in reducing C difficile with electronic hand hygiene monitoring, advancing HIV prevention with lenacapavir, updating COVID-19 vaccines for high-risk groups, and more.

Spikevax and mNEXSPIKE authorized for older adults and high-risk individuals; experts emphasize protection against severe COVID-19 outcomes.

UNC’s Sarah Rutstein, MD, PhD, discusses her research uncovering the inability of some people to receive HIV prevention medication in both the US and Africa and strategies to address it.

New authorization limits shots to adults ≥65 and individuals with underlying health conditions, with ACIP set to review guidance and insurance coverage implications.

C difficile remains a major healthcare-associated infection. Despite clear guidelines, hand hygiene compliance often falls short, creating gaps between policy and practice. A case study from a hospital showed that after implementing an electronic hand hygiene monitoring system with behavior prompts, compliance improved.

CDC encourages travelers to take enhanced precautions, get vaccinated, and prevent mosquito bites in affected areas, with special warnings for pregnant individuals.

Joseph Eron, MD, provides insights on the unit's international reach as well as some of the important trials it has been involved in, notably the PURPOSE studies involving the landmark trials about lenacapavir for HIV prevention.